Maravai LifeSciences Holdings

MRVI

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Good

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Maravai LifeSciences makes specialized ingredients and tools that other biotech and pharmaceutical companies use to develop drugs, vaccines, and genetic medicines. Its main products include nucleic acid raw materials (like the building blocks used to make mRNA), reagents for detecting biological molecules, and other research supplies. The company became well known for supplying key materials used in mRNA-based COVID-19 vaccines.

Maravai earns revenue by selling these materials and tools directly to drug developers, vaccine makers, and research institutions, primarily in North America and Europe. With roughly $1.7 billion in market cap, it is a mid-sized supplier in the life sciences tools industry, and its competitive edge comes from specialized manufacturing know-how that is difficult to replicate quickly. The biggest risk the company faces is that demand for mRNA-related materials dropped sharply after the COVID-19 vaccine boom ended, and its future growth depends heavily on whether new mRNA-based drugs and therapies advance successfully through clinical development.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+8.5% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+70.4% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

30.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$70M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Maravai LifeSciences Holdings is growing revenue at 9% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

40.1%

Healthy — 40.1% gross margin

Profit after running costs

Operating Margin

-29.3%

Losing money on operations — -29.3%

Return on the money invested

ROCE

27.3%

Exceptional — 27.3% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-3.3%

Shrinking sales (-3.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-16.8%

Burning cash (-16.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.72

Moderate — manageable debt (0.72)

Covers its interest

Interest Cover

4.01x

Adequate interest coverage (4.0x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial